Lutris Pharma Ltd.   Report issue

For profit Phase 2
Founded: Tel Aviv Israel (2016)

Organization Overview

First Clinical Trial
2019
NCT03876106
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Lutris Pharma Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

lut014 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 1)

Dermatitis (Phase 2)

Radiodermatitis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1